Cite
MLA Citation
T. Price et al.. “2110 Efficacy outcomes by severity of skin toxicity from ASPECCT: Randomized phase 3 study of panitumumab (pmab) versus cetuximab (cmab) in chemorefractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC).” European journal of cancer, vol. 51, n.d., pp. S366–. http://access.bl.uk/ark:/81055/vdc_100030628213.0x000024